RWP
GALT icon

RWA Wealth Partners’s Galectin Therapeutics GALT Stock Holding History

RWA Wealth Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,500
Closed -$29K – 423
2018
Q2 		$29K Buy
+4,500
New +$21.9K ﹤0.01% 486

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

RWA Wealth Partners's GALT Position: Q3 2018 in Review

RWA Wealth Partners sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 4,500 shares — an estimated $29K sold.

RWA Wealth Partners first reported a position in GALT in Q2 2018 and held it in 1 quarter. The position peaked at $29K in Q2 2018. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

  • RWA Wealth Partners reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
  • RWA Wealth Partners sold 4,500 Galectin Therapeutics shares in Q3 2018, an estimated $29K.
  • RWA Wealth Partners first reported a position in Galectin Therapeutics in Q2 2018 and held it in 1 quarter.
  • RWA Wealth Partners's Galectin Therapeutics position peaked at $29K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on RWA Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.